CABA

Cabaletta Bio Inc. (CABA) | Rumor.io

Cabaletta Bio

CABA

Attention (50-day avg)0%

Attention rank (50-day avg)#946

Bullish sentiment (50-day avg)84%

Price to earnings ratio-0.95

Market capitalization339.1M

Earnings per share-1.38

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-167.9M

Social

What share of all stock conversation is about CABA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 29

Cabaletta Bio, Inc. ($CABA) may be at a bottom price, and a buying opportunity, with a technical analysis perspective suggesting a potential 25% squeeze.
The market is assigning zero option value to a potential 2H26 print of the company's PC-free data, which could be a real catalyst, but not a BLA catalyst.
The stock is in a strong downtrend, and there is currently no news regarding the drug, making a rise to $2.50 highly unlikely, and potentially falling into the penny stock range.

Generated by AI

Sentiment

Of the messages about CABA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +8.33	70% +1.18	80.69% -11.46	87.7% +1.89
Bearish	50% -8.33	30% -1.18	19.31% +11.46	12.3% -1.89

Bullish· Sep 23

Insiders and institutions are buying at current prices, with one post noting that they're purchasing at levels lower than they paid earlier in the year, indicating a potential opportunity for retail investors.
The company has a strong cash position, with $300M in the bank, and is expected to receive crucial data updates in November, which could be a catalyst for the stock.
The post mentions a "coiled spring" and "rocket fuel" in relation to the massive short interest in the stock, suggesting that the short position could become a significant factor in the stock's price movement.

Bearish· Jun 9

The stock has been trading near support levels despite positive data and manufacturing progress, implying little success and potential for a big move down.
The OBV indicator suggests that even smart money has left the stock, and the game is over, indicating a lack of investor confidence.
The stock has recovered from a significant drop, but the author is skeptical about the current price level and believes it may fall further, with some speculating it could drop to $30 or fail altogether.

Generated by AI

Topics

Of the messages about CABA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	10%	62.67%	44.96%
Technical Analysis	100%	90%	30.67%	31.13%
Analysts	0%	0%	5.33%	14.55%
Earnings	0%	0%	0%	0.61%
Macro	0%	0%	1.33%	8.65%
Controversies	0%	0%	0%	0.11%

Announcements· Oct 9

Cabaletta Bio's rese-cel treatment achieved complete B-cell depletion and rapid symptom improvement in pemphigus vulgaris patients without preconditioning.
The company reported early positive responses in three patients treated with rese-cel, including significant improvements in Pemphigus Disease Area Index (PDAI).
Cabaletta Bio is moving forward with registrational myositis cohorts in H2 2025 and has a capital raise that extends its runway for further development.

Controversies· Mar 7

$CABA is involved in a securities class action, with a deadline for investors to secure counsel.
A video about CABA Stock is shared, explaining the company and clearing up doubts for viewers.
CABA Stock has experienced a significant loss, according to an anonymous news source.

Technical Analysis· Dec 2

CABA is up heavy after hours and ready to run, with a strong break of $4.60 needed to test new resistances and reach the $6 dollar mark.
CABA has formed a quadruple top breakout on the P&F chart, with moving up on high volume and no news, and a gapped up at the open, corrected, and heading back up now.
CABA has resistance and first target at $4.90-5, possibly to $5.59 & $6+, with support at $4.40-42, and is trending over the EMAs with 56.9% so far.

Generated by AI

Community

Of the messages about CABA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	59.46%	78.17%	81.82%	60.91%
Newcomers	40.54%	21.83%	18.18%	39.09%

Regulars· Sep 28

The company has a cash reserve of $350 million, but its market cap is also $350 million, leading some to question whether it is adding value to its existing assets.
There is anticipation of a near-term event that could trigger a brief price increase before a potential dilution event, with the company needing an infusion of capital to continue its research.
Some investors believe that the stock price and company fundamentals will eventually align, and that the company's potentially lucrative research and institutional support will ultimately justify its declining stock price.

Newcomers· Jul 2

Many newcomers are focused on the potential of Cabaletta Bio, Inc. ($CABA) as a long-term investment opportunity.
Some are concerned about the high risk associated with a single data readout, which could impact the stock's price.
Others are hoping for a "binary event" that could trigger a significant price increase, and are speculating about the timing of such an event.

Generated by AI

News

Cabaletta Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Meetings with investors on Tuesday, September 8, 2026, in Boston, MA.2026 Cantor Global Healthcare Conference: M

28d agoYahoo Finance

Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA)

Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress

1mo agoInvesting.com

Also Discussed

Investors talking about CABA also mention

#	Name	Attention
1	Autolus Therapeutics plc ADRAUTL	0%+0
2	Kyverna Therapeutics, Inc.KYTX	0%0
3	Cullinan Therapeutics Inc.CGEM	0%new
4	4D Molecular Therapeutics, Inc.FDMT	0%new
5	IDEAYA Biosciences Inc.IDYA	0%-0.01
6	Nkarta, Inc.NKTX	0%0
7	GRCL - Gracell Biotechnologies Inc.	——
8	Bicycle Therapeutics plc - ADRBCYC	0%0
9	Tenaya Therapeutics, Inc.TNYA	0.01%0
10	SLRN - Acelyrin, Inc.	——

Cabaletta Bio Inc.

Healthcare
Biotechnology

Cabaletta Bio Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company’s current programs center on targeted cell therapies designed to selectively eliminate disease-causing B cells while sparing healthy immune function. Its lead candidate, rese-cel, is being studied in the RESET clinical development program across autoimmune conditions including lupus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Cabaletta Bio also advances CAAR T cell approaches through its broader CABA platform, which is intended to address B cell–mediated autoimmune disorders. Based in Philadelphia, Cabaletta Bio plays a specialized role in the cell therapy market by focusing on precision immunology and disease-modifying treatments for patients with severe autoimmune disease.

Website

Location

2929 Arch Street

Philadelphia, PA, 19104

United States

Social

What share of all stock conversation is about CABA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 29

Cabaletta Bio, Inc. ($CABA) may be at a bottom price, and a buying opportunity, with a technical analysis perspective suggesting a potential 25% squeeze.
The market is assigning zero option value to a potential 2H26 print of the company's PC-free data, which could be a real catalyst, but not a BLA catalyst.
The stock is in a strong downtrend, and there is currently no news regarding the drug, making a rise to $2.50 highly unlikely, and potentially falling into the penny stock range.

Generated by AI

Sentiment

Of the messages about CABA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +8.33	70% +1.18	80.69% -11.46	87.7% +1.89
Bearish	50% -8.33	30% -1.18	19.31% +11.46	12.3% -1.89

Bullish· Sep 23

Insiders and institutions are buying at current prices, with one post noting that they're purchasing at levels lower than they paid earlier in the year, indicating a potential opportunity for retail investors.
The company has a strong cash position, with $300M in the bank, and is expected to receive crucial data updates in November, which could be a catalyst for the stock.
The post mentions a "coiled spring" and "rocket fuel" in relation to the massive short interest in the stock, suggesting that the short position could become a significant factor in the stock's price movement.

Bearish· Jun 9

The stock has been trading near support levels despite positive data and manufacturing progress, implying little success and potential for a big move down.
The OBV indicator suggests that even smart money has left the stock, and the game is over, indicating a lack of investor confidence.
The stock has recovered from a significant drop, but the author is skeptical about the current price level and believes it may fall further, with some speculating it could drop to $30 or fail altogether.

Generated by AI

Topics

Of the messages about CABA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	10%	62.67%	44.96%
Technical Analysis	100%	90%	30.67%	31.13%
Analysts	0%	0%	5.33%	14.55%
Earnings	0%	0%	0%	0.61%
Macro	0%	0%	1.33%	8.65%
Controversies	0%	0%	0%	0.11%

Announcements· Oct 9

Cabaletta Bio's rese-cel treatment achieved complete B-cell depletion and rapid symptom improvement in pemphigus vulgaris patients without preconditioning.
The company reported early positive responses in three patients treated with rese-cel, including significant improvements in Pemphigus Disease Area Index (PDAI).
Cabaletta Bio is moving forward with registrational myositis cohorts in H2 2025 and has a capital raise that extends its runway for further development.

Controversies· Mar 7

$CABA is involved in a securities class action, with a deadline for investors to secure counsel.
A video about CABA Stock is shared, explaining the company and clearing up doubts for viewers.
CABA Stock has experienced a significant loss, according to an anonymous news source.

Technical Analysis· Dec 2

CABA is up heavy after hours and ready to run, with a strong break of $4.60 needed to test new resistances and reach the $6 dollar mark.
CABA has formed a quadruple top breakout on the P&F chart, with moving up on high volume and no news, and a gapped up at the open, corrected, and heading back up now.
CABA has resistance and first target at $4.90-5, possibly to $5.59 & $6+, with support at $4.40-42, and is trending over the EMAs with 56.9% so far.

Generated by AI

Community

Of the messages about CABA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	59.46%	78.17%	81.82%	60.91%
Newcomers	40.54%	21.83%	18.18%	39.09%

Regulars· Sep 28

The company has a cash reserve of $350 million, but its market cap is also $350 million, leading some to question whether it is adding value to its existing assets.
There is anticipation of a near-term event that could trigger a brief price increase before a potential dilution event, with the company needing an infusion of capital to continue its research.
Some investors believe that the stock price and company fundamentals will eventually align, and that the company's potentially lucrative research and institutional support will ultimately justify its declining stock price.

Newcomers· Jul 2

Many newcomers are focused on the potential of Cabaletta Bio, Inc. ($CABA) as a long-term investment opportunity.
Some are concerned about the high risk associated with a single data readout, which could impact the stock's price.
Others are hoping for a "binary event" that could trigger a significant price increase, and are speculating about the timing of such an event.

Generated by AI

Cabaletta Bio

Social

Sep 29

Bullish· Sep 23

Bearish· Jun 9

Announcements· Oct 9

Controversies· Mar 7

Technical Analysis· Dec 2

Regulars· Sep 28

Newcomers· Jul 2

Cabaletta Bio at Morgan Stanley conference: safety and scale in focus

Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration

Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale

Cabaletta Bio to Participate in Upcoming Investor Conferences

Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA)

Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress

Also Discussed

Cabaletta Bio Inc.

Company Information

Location

Cabaletta Bio at Morgan Stanley conference: safety and scale in focus

Cabaletta Bio raises $128.2 million from warrant exercises ahead of expiration

Cabaletta Bio at cantorfitzgerald healthcare conference: safety and scale

Cabaletta Bio to Participate in Upcoming Investor Conferences

Wells Fargo Sticks to Their Hold Rating for Cabaletta Bio (CABA)

Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress

Also Discussed

Social

Sep 29

Bullish· Sep 23

Bearish· Jun 9

Announcements· Oct 9

Controversies· Mar 7

Technical Analysis· Dec 2

Regulars· Sep 28

Newcomers· Jul 2